Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (4882)	11/9/2003 12:41:04 PM
From: StockDung	Respond to of 5582

If all this is true Dan, can you please tell everyone what MTXX's insurance coverage is including deductable amount per case. per case limit and total limit? Can you also tell us what MTXX's insurance policy says about pre exisiting but not disclosed product liablities? Since Intranasal Zinc problems were publicly disclosed in the QGLY vs GUMM/MTXX lawsuit, one would think that MTXX would have disclosed this when applying to their insurance company for product liablity coverage. DID THEY DAN? And please tell us why MTXX is making legal threats to the good Dr. Bruce Jafek in an attempt to keep the world from knowing the evil truth about zinc. Why would a legitimate company try to stifel the truth about its products when one of the worlds greatest Rhinologists wants to tell everyone about it? What is it MTXX is trying to hide. Dan can you sleep at night knowing what this non FDA approved drug does to people? Have you know conscience? Or is it all about Makemillions?

To: DanZ who wrote (4882)	11/9/2003 3:51:34 PM
From: StockDung	Respond to of 5582

Diploma Mills - Fraud in Higher Education degreeinfo.com

To: DanZ who wrote (4882)	11/9/2003 4:28:51 PM
From: StockDung	Respond to of 5582

PERSISTENT ANOSMIA FOLLOWING ZINC SULFATE NASAL SPRAYING F.F. TISDALL, M.D. ALAN BROWN, M.D. and R.D. DEFRIES, M.D. Toronto, Ont. From the hospital for Sick Children and the School of Hygiene and Connaught Laboratories. University of Toronto _________ Reprinted from THE JOURNAL OF PEDIATRICS St. Louis _________ Vol. 18, No. 1, Pages 60 – 02, July, 1938 ================================================

To: DanZ who wrote (4882)	11/10/2003 6:27:45 PM
From: StockDung	Respond to of 5582

ACTISYN From SPORTPHARMA Last month I reviewed a new product put out by SportPharma called Actisyn. I went on record stating that I was skeptical about SportPharma’s claim that Actisyn increases protein synthesis in the body 640% better than ion-exchange whey protein. It appears my hunch that the advertising surrounding Actisyn was misleading and primarily “hype” has been substantiated. I have a document dated May 6, 1999 that states, “the United States District Court for the Southern District of California found that SportPharma USA published false and misleading claims in advertising and product labeling for its new supplement product, Actisyn.” Judge Napoleon A. Jones Jr. has ordered SportPharma to recall all “Actisyn” products and promotional material containing statements that the court found to be false or misleading. He also ordered Sportpharma to pay Next Nutrition (the makers of Designer Protein) a $50,000 damage award for “making disparaging representations” of Designer Protein. In light of this ruling anyone who purchased Actisyn from my store may return the remaining portions or the empty can for FULL CREDIT. Not to say I told you so, but I knew those claims were a little far fetched when I first read them. Needless to say all SportPharma products carried in my store will undergo thorough testing and the results will be posted in upcoming newsletters. RATING: •• 216.239.37.104

To: DanZ who wrote (4882)	11/10/2003 6:30:28 PM
From: StockDung	Respond to of 5582

THE EFFECT OF ACTISYN ON ANABOLIC HORMONAL PROFILES AND ACTIN AND MYOSIN mRNA AND PROTEIN LEVELS IN EXERCISED RAT AND HUMAN. Charles B. Hensley, R. Steven Davidson and Stephan N. Mayer Human Performance Institute A Division of Biotem Cytotechnologies

To: DanZ who wrote (4882)	11/12/2003 12:17:57 PM
From: StockDung	Respond to of 5582

We may incur significant costs resulting from product liability claims We are subject to significant liability should use or consumption of our products cause injury, illness or death. Although we carry product liability insurance, there can be no assurance that our insurance will be adequate to protect us against product liability claims or that insurance coverage will continue to be available on reasonable terms. A product liability claim, even one without merit or for which we have substantial coverage, could result in significant legal defense costs, thereby increasing our expenses and lowering our earnings. Such a claim, whether or not proven to be valid, could have a material adverse effect on our product branding and goodwill, resulting in reduced market acceptance of our products. This in turn could materially adversely affect our results of operations and financial condition.